Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 17/20 | 0.47 |
| ▸ | PTPN1 | P18031 | 3/20 | 0.46 |
| ▸ | CTSD | P07339 | 1/20 | 0.42 |
| ▸ | BACE2 | Q9Y5Z0 | 2/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29881615 | 0.99 | PTPN1 (0.47) | BACE1PTPN1CTSDBACE2 | |
| SCHEMBL29777847 | 0.94 | BACE1 (0.49) | BACE1PTPN1CTSDBACE2 | |
| SCHEMBL30770813 | 0.94 | BACE1 (0.40) | BACE1PTPN1CTSDBACE2 | |
| SCHEMBL30607941 | 0.93 | BACE1 (0.41) | BACE1PTPN1CTSD | |
| SCHEMBL29511114 | 0.93 | BACE1 (0.41) | BACE1PTPN1CTSD | |
| SCHEMBL30719918 | 0.91 | BACE1 (0.44) | BACE1PTPN1CTSDBACE2 | |
| SCHEMBL29777860 | 0.91 | BACE1 (0.45) | BACE1PTPN1CTSDBACE2 | |
| SCHEMBL30839281 | 0.90 | PTPN1 (0.41) | BACE1PTPN1CTSDBACE2 | |
| SCHEMBL30142012 | 0.90 | PTPN1 (0.39) | BACE1PTPN1CTSDBACE2 | |
| SCHEMBL29461611 | 0.89 | BACE1 (0.39) | BACE1PTPN1CTSD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3703755-B1 | COMBINATION COMPRISING AT LEAST ONE SPLICEOSOME MODULATOR AND AT LEAST ONE INHIBITOR CHOSEN FROM BCL2 INHIBITORS, BCL2/BCLXL INHIBITORS, AND BCLXL INHIBITORS FOR USE IN THE TREATMENT OF CANCER | EISAI R&D MAN CO LTD (JP) | 2024-07-31 | — | — | EP | claimed |
| EP-3514154-B1 | PLADIENOLIDE PYRIDINE COMPOUNDS AND METHODS OF USE | EISAI R&D MAN CO LTD (JP) | 2022-08-03 | — | — | EP | claimed |
| US-20260117176-A1 | MODIFIED IMMUNE EFFECTOR CELLS WITH IMPROVED EFFICACY | BEAM THERAPEUTICS INC. (US) | 2026-04-30 | — | — | US | disclosed |
| US-12460204-B2 | Artificial nucleic acid molecules for improved protein or peptide expression | CureVac SE (DE) | 2025-11-04 | — | — | US | disclosed |
| US-12415844-B2 | BCMA specific VCAR compositions and methods for use | POSEIDA THERAPEUTICS, INC. (US) | 2025-09-16 | — | — | US | disclosed |
| US-12352767-B2 | Method of treating cognitive decline associated with neurological diseases based on a decrease in FLT4 expression or activity | UNIVERSITY OF VIRGINIA PATENT FOUNDATION (US) | 2025-07-08 | — | — | US | disclosed |
| US-20250051846-A1 | GENOME-WIDE CLASSIFIERS FOR DETECTION OF SUBACUTE TRANSPLANT REJECTION AND OTHER TRANSPLANT CONDITIONS | SCRIPPS RESEARCH INST (US) | 2025-02-13 | — | — | US | disclosed |
| US-12209283-B2 | Genome-wide classifiers for detection of subacute transplant rejection and other transplant conditions | THE SCRIPPS RESEARCH INSTITUTE (US) | 2025-01-28 | — | — | US | disclosed |
| US-12195800-B2 | Method to predict heritable canine non-contact cruciate ligament rupture | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2025-01-14 | — | — | US | disclosed |
| EP-4372090-A2 | CRISPR-RELATED METHODS AND COMPOSITIONS WITH GOVERNING GRNAS | Editas Medicine, Inc. (US) | 2024-05-22 | — | — | EP | disclosed |
| US-20240067992-A1 | HUMAN HEMATOPOIETIC STEM CELL HAVING A MODIFIED BCL11A GENE AND METHODS OF MAKING THE CELL | EDITAS MEDICINE, INC. (US) | 2024-02-29 | — | — | US | disclosed |
| EP-3363903-B1 | CRISPR-RELATED METHODS AND COMPOSITIONS WITH GOVERNING GRNAS | EDITAS MEDICINE INC (US) | 2024-01-03 | — | — | EP | disclosed |
| US-20230323290-A1 | CELLS USEFUL FOR IMMUNO-BASED BOTULINUM TOXIN SEROTYPE A ACTIVITY ASSAYS | ALLERGAN INC (US) | 2023-10-12 | — | — | US | disclosed |
| US-11644466-B2 | Methods for treating, preventing and predicting risk of developing breast cancer | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-05-09 | — | — | US | disclosed |
| US-11624093-B2 | Tumor suppressor and oncogene biomarkers predictive of anti-immune checkpoint inhibitor response | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2023-04-11 | — | — | US | disclosed |
| US-20230047556-A1 | ANTI-INFLAMMATORY PROPERTIES OF MARINE LIPID COMPOSITIONS | AKER BIOMARINE HUMAN INGREDIENTS AS (NO) | 2023-02-16 | — | — | US | disclosed |
| US-20220389460-A1 | CRISPR-RELATED METHODS AND COMPOSITIONS WITH GOVERNING gRNAS | EDITAS MEDICINE, INC. (US) | 2022-12-08 | — | — | US | disclosed |
| US-20220389077-A1 | ALLOGENEIC CELL COMPOSITIONS AND METHODS OF USE | POSEIDA THERAPEUTICS, INC. | 2022-12-08 | — | — | US | disclosed |
| US-11400105-B2 | Anti-inflammatory properties of marine lipid compositions | AKER BIOMARINE ANTARCTIC AS (NO) | 2022-08-02 | — | — | US | disclosed |
| US-11390887-B2 | CRISPR-related methods and compositions with governing gRNAS | EDITAS MEDICINE, INC. (US) | 2022-07-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11400105-B2 | Anti-inflammatory properties of marine lipid compositions | PTGES3, ELOVL3, PTGER3 | BACE1 2119/4885PTPN1 2583/4885CTSD 1542/4885 |
| US-20230047556-A1 | ANTI-INFLAMMATORY PROPERTIES OF MARINE LIPID COMPOSITIONS | PTGES3, ELOVL3, PTGER3 | BACE1 2119/4885PTPN1 2583/4885CTSD 1542/4885 |
| US-12460204-B2 | Artificial nucleic acid molecules for improved protein or peptide expression | RNMT, NSUN3, RNGTT | BACE1 4510/4885PTPN1 4475/4885CTSD 2990/4885 |
| US-20240067992-A1 | HUMAN HEMATOPOIETIC STEM CELL HAVING A MODIFIED BCL11A GENE AND METHODS OF MAKING THE CELL | MCL1, BCL2L11, BCL2L13 | BACE1 4625/4885PTPN1 2982/4885CTSD 2781/4885 |
| US-20260117176-A1 | MODIFIED IMMUNE EFFECTOR CELLS WITH IMPROVED EFFICACY | EIF2AK2, TIA1, NFATC1 | BACE1 3796/4885PTPN1 1116/4885CTSD 3930/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.